Summary:
This podcast features a panel discussion with pharma and biotech leaders about the past and future direction of pulmonary delivery of biologics. Specifically, the panelists discuss:
- The benefits and costs of different formulation approaches to deliver inhaled therapeutics what needs to be developed to enable more biologics
- Different device approaches including nebulizers, soft mist inhalers, dry powder inhalers and more
- Factors driving new platform and therapeutic development including patient-centricity, legacy technology and time to market
- Next-generation inhaled therapeutics like mRNA vaccines
To learn more about the PODD conference, please visit Drug-Delivery.org.
Moderators
Michael Song, PhD
Director
Moderna
Panelists
Philippe Rogueda, PhD, FRSC, CChem, CSci
CBO
Merxin Ltd
Alessandro Cavecchi, M.Sc.
Head of Pharmaceutical Technology
Chiesi Farmaceutici S.p.A.
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.